Elranatamab

Overview

Elranatamab is a B-cell Maturation Antigen (BCMA)-CD3 bispecific antibody being tested in multiple myeloma.

SparkCures ID 302
Developed By Pfizer
Generic Name Elranatamab
Additional Names PF-06863135
Treatment Classifications
Treatment Targets
Tags

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Pfizer Presents First Data from Planned Interim Analysis of Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab Under Investigation for Relapsed/Refractory Multiple Myeloma

June 05, 2022

In this interim analysis, safety and efficacy was analyzed in 94 patients who had received at least one dose of elranatamab (Cohort A – BCMA-naïve) as of the data cutoff on March 23, 2022. Patients received subcutaneous (SC) elranatamab 76 mg weekly (QW) with a 2-step-up priming dose regimen administered during the first week. With a median follow up of 3.71 months, initial efficacy results showed that the objective response rate for elranatamab was 60.6%. As of the data cut-off, 89.5% of objective responders were ongoing without confirmed progression or death.

Resources